Preparation of 5-Fluorouracil for Clinical Use
5-Fluorouracil (5-FU) is commercially available as a 5% topical cream that requires no special preparation beyond direct application to the affected area using a non-metal applicator or gloved hand. 1
Topical Formulation
The standard preparation is 5-fluorouracil topical solution USP, 5%, which contains:
- 5% fluorouracil (weight/weight basis)
- Compounded with: edetate disodium, hydroxypropyl cellulose, methylparaben, propylparaben, propylene glycol, purified water, and tromethamine 1
Application Method
Apply the cream directly to lesions using:
- A non-metal applicator (preferred), OR
- A suitable glove
- If applied with bare fingers, wash hands immediately afterward 1
Dosing Regimens by Indication
For Actinic Keratosis
- Apply twice daily for 2-4 weeks until inflammatory response reaches erosion stage 1
- Complete healing may take 1-2 months after stopping treatment 1
- Maximum treatment area: 500 cm² due to toxicity concerns 2
For Bowen's Disease (SCC in-situ)
- Standard regimen: Once or twice daily for 3-4 weeks 3, 4
- Alternative intensive regimen: Once daily for 1 week, then twice daily for 3 weeks 4
- May require 1 week to 2 months depending on lesion response 3
For Superficial Basal Cell Carcinoma
- Apply twice daily for 3-6 weeks minimum 1
- May require up to 10-12 weeks for complete lesion obliteration 1
Important Preparation Considerations
Lower concentrations (<5%) are less effective and not recommended 3. The 5% concentration is the evidence-based standard across all guidelines 2.
Alternative Formulation
- 5-FU 0.5% in 10% salicylic acid is available as an alternative preparation, where salicylic acid may enhance penetration 2
Storage and Stability
For intravenous preparations (when applicable):
- 5-FU 8 mg/mL in 0.9% sodium chloride can be prepared in advance
- Stable when frozen at -20°C for 79 days
- After microwave thawing, stable for 28 days at 5°C ± 3°C in PVC bags 5
Critical Safety Points
Before initiating 5-FU therapy:
- Test for dihydropyrimidine dehydrogenase (DPD) deficiency when using systemic fluoropyrimidines 6
- Counsel patients about expected inflammatory response: erythema → vesiculation → desquamation → erosion → re-epithelialization 1
Manage side effects by:
- Taking treatment breaks
- Reducing application frequency
- Applying thin emollient (permitted during treatment)
- Using weak topical steroid if reaction is excessive 2
Exercise caution at poor healing sites (especially lower legs in elderly patients) - may require supervision or observation rather than treatment 3, 2, 4